Recent

% | $
Quotes you view appear here for quick access.

Nxstage Medical, Inc. Message Board

cigar_roooms_guy 748 posts  |  Last Activity: Dec 29, 2015 11:02 AM Member since: Jan 4, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • cigar_roooms_guy by cigar_roooms_guy Dec 29, 2015 11:02 AM Flag

    It cost over one billion dollars to bring a drug to approval. Ten years and a 93% chance it won't get approved. So when you say the companies are charging too much have your liberal nut bags cute he drug companies fees and they will stop trying to cure you or your family member of a dibiliting disease
    Hilary is a liar and a spin doctor

  • cigar_roooms_guy by cigar_roooms_guy Nov 25, 2015 5:41 PM Flag

    Is that too much

  • Reply to

    i'm nervous about the call monday morning

    by walkingon_air2002 Nov 20, 2015 11:35 PM
    cigar_roooms_guy cigar_roooms_guy Nov 23, 2015 3:55 AM Flag

    You won't see earnings until Monday at midnight Ireland is 8 hours behind

  • cigar_roooms_guy by cigar_roooms_guy Oct 25, 2015 6:23 AM Flag

    She's never been in business. So she has given the doctors and hospitals free reins to charge more money. They can tell the insurance companies these are our rates take it or leave it.. And guess what the insurance companies will have to play the doctors games but just raise there rates. Combine the insurance companies and they give the doctors and hospitals no choice but to play by there rules lower your feesdoc o more million dollar salaries that will result in lower insurance rates. Democrates are blue collar workers and don't understand how business works

  • cigar_roooms_guy by cigar_roooms_guy Oct 17, 2015 7:15 PM Flag

    Financial firms that have lax cybersecurity practices can expect a crackdown from regulators, the head of the Securities and Exchange Commission’s enforcement unit said Friday.

    “If firms don’t have appropriate policies and procedures in place, that could be a [regulation S-P] violation,” the director of the SEC’s Division of Enforcement, Andrew Ceresney said, referring to a rule that requires financial institutions to protect customer information.

    After Scottrade, 5 things to know about the safety of your investments

    The warning from the regulator five months after the SEC released results from a cybersecurity survey of 57 registered broker-dealers and 49 investment advisers, which sought to gauge whether firms are prepared against cyber criminals and what risks they may face. It found that 88% of broker-dealers and 74% of advisers have experienced cyber attacks, either directly or through a vendor. The Financial Industry Regulatory Authority, Wall Street’s self-regulator, conducted a similar survey, and both have since issued guidance as to how firms should best handle growing cyber threats.

    Most brokers and advisers don’t guarantee your money back after a hack attack

    Last month, the agency charged a St.Louis-based investment adviser last month for failing to follow adequate security practices like encrypting client information, assessing its risks and developing a response plan for after hacks. It fined R.T. Jones Capital Equities Management $75,000. The case was considered among the first against a firm for cybersecurity issues. Consequences of a case can vary, from fines to cease and desist orders, suspension or revocation of broker-dealer and investment adviser registrations, censures bars from association with the securities industry and other penalties.

    Earlier this month, the brokerage Scottrade said

  • cigar_roooms_guy by cigar_roooms_guy Oct 16, 2015 12:38 PM Flag

    Facebook
    Google Plus
    linkedin
    Twitter

    Three Best Stocks in the News: Mallinckrodt PLC (NYSE:MNK), ONEOK, Inc. (NYSE:OKE), CIT Group Inc. (NYSE:CIT)
    Oct 16, 2015Lisa WalkerBusiness & Finance0


    On Thursday, Shares of Mallinckrodt PLC (NYSE:MNK), gained 2.01% to $66.90.

    Mallinckrodt plc, declared that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology (ACR) 2015 Annual Meeting to be held November 7-11 in San Francisco.

    Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.

  • cigar_roooms_guy by cigar_roooms_guy Oct 6, 2015 8:58 AM Flag

    Cramer tell him he needs to listen to the CC and retract

  • cigar_roooms_guy by cigar_roooms_guy Aug 30, 2015 12:43 PM Flag

    It seems like if a warren buffet type of guy tried to buy Cigna the SEC issues would go away and it would go for more money. This is a cash cow

  • Reply to

    Navellier

    by pere_joseph Jul 29, 2015 10:38 AM
    cigar_roooms_guy cigar_roooms_guy Jul 29, 2015 10:47 AM Flag

    No he picked mei went from 46 to 26. He picked a stock with a 50% short ownership. My subscription is over he's too into himself and his palm beach homes can you say madoff

  • cigar_roooms_guy by cigar_roooms_guy Jul 28, 2015 7:16 AM Flag

    270m chump change no effect at all

  • cigar_roooms_guy by cigar_roooms_guy Jul 21, 2015 4:04 PM Flag

    The second stock I want to tell you about is Sucampo Pharmaceuticals (SCMP). It's a little-known biopharmaceutical, only four analysts are following it, but it has explosive potential. The company is focused on the research and development of proprietary drugs to treat gastrointestinal, neurologic, ophthalmic and oncology-based inflammatory disorders. Its leading treatment is AMITIZA, which is used to treat chronic idiopathic constipation, irritable bowel syndrome and opioid-induced constipation.

    Recently, the company received Fast Track Designation from the FDA for cobiprostone, a treatment used to prevent oral mucositis. This is great news, as Fast Track Designation expedites the development and review of treatments for serious conditions. And the FDA also accepted an Investigational New Drug application for a phase II clinical trial of cobiprostone.

    In the first quarter, Sucampo Pharmaceuticals' earnings surged a stunning 700% year-over-year, while sales increased 33%. The second quarter is lining up to be just as impressive: Analysts are looking for earnings of $0.16 per share on $31.85 million in sales, which translates to 300% annual earnings growth and 32% annual sales growth.

    Given the strength of its sales and earnings growth, SCMP earns an A fundamental grade and an A quantitative grade. It receives A ratings for sales growth, operating margin growth, earnings growth, earnings momentum, analyst earnings revisions and return on equity. Earnings surprises earns a C rating, while cash flow gets a B rating. Overall, SCMP is an A-rated Strong Buy.

  • cigar_roooms_guy by cigar_roooms_guy Jun 18, 2015 3:51 PM Flag

    With a PEG of only .70 and earnings of 9 dollars per share with a market cap on only 10 billion and doing business in another county with all the recent buyouts and a blockbuster drug with 30 on the way to the FDA this will get bought for over 200 a share

  • cigar_roooms_guy by cigar_roooms_guy Apr 20, 2015 12:34 PM Flag

    In earnings this stock is so undervalued

  • cigar_roooms_guy by cigar_roooms_guy Apr 19, 2015 9:50 AM Flag

    Anything below 1.00 Some things to ponder
    Here are a few more interesting tidbits from my study:

    92% of companies with PEG ratios of less than 1 beat the market over three years.
    68% of companies with PEG ratios of between 1 and 2 beat the market.
    47% of companies with PEG ratios greater than 2 beat the market.
    The best performer was (surprise, surprise) Hansen Natural (Nasdaq: HANS ) . It had a PEG of 0.08 in 2003 and had gained 5,400% through March.
    The second-best performer was NutriSystem (Nasdaq: NTRI ) with a PEG of 0.06 and a gain of 5,200%.
    Despite a PEG of 0.55, Ford (NYSE: F ) managed only a 14% gain over three years.
    #$%$ Sporting Goods (NYSE: DKS ) was "fairly valued" with a PEG of exactly 1, but it still appreciated by 265%.
    A PEG of 8 didn't stop Select Comfort (Nasdaq: SCSS ) from appreciating by 266%.

  • cigar_roooms_guy by cigar_roooms_guy Apr 10, 2015 8:59 AM Flag

    Canaccord Genuity took the other route, raising its price target to $150 from $145 based on higher market share for the iPhone 6.

    Read more: Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More - Apple Inc. (NASDAQ:AAPL) - 24/7 Wall St. http://247wallst.com/investing/2015/04/10/top-analyst-upgrades-and-downgrades-apple-citrix-kythera-mylan-netflix-weatherford-and-more/#ixzz3WuWmJApd
    Follow us: @247wallst on Twitter | 247wallst on Fac

  • cigar_roooms_guy by cigar_roooms_guy Apr 9, 2015 8:04 AM Flag

    Louis Navellier has this as a top pick buy under 149

  • Reply to

    INSY buyout chatter?

    by joe82man Apr 7, 2015 10:21 PM
    cigar_roooms_guy cigar_roooms_guy Apr 8, 2015 11:56 AM Flag

    A source familiar with the matter told Benzinga Tuesday that Mallinckrodt PLC (NYSE: MNK) was in talks to acquire Insys Therapeutics Inc(NASDAQ: INSY) in a transaction valuing shares at around $65.

    Shares of Insys were trading higher by more than 6 percent Wednesday.

    Speaking to Benzinga on Wednesday, Oppenheimer analyst Akiva Felt said that progression of rumor between the two companies is "still stagnant," but he added that it "fits into" Mallinckrodt's strategy.

    The analyst also added that he "doesn't know why it would be more likely now versus four months ago."

    Finally, when asked if a consolidation is expected between large biotech companies and smaller cannabis companies, Felt suggested that analysts are "talking down" on M&A chatter of that magnitude.

    Sent from my iPhone

  • cigar_roooms_guy by cigar_roooms_guy Mar 27, 2015 8:27 AM Flag

    Way too cheap earnings growing

  • Reply to

    hey, what happened to that $140 price target?

    by gizzy2020 Mar 25, 2015 10:18 AM
    cigar_roooms_guy cigar_roooms_guy Mar 25, 2015 10:59 AM Flag

    Yup it's got a peg of under.80 it's so cheap just a little rebalance getting the weak hands out its a great company

  • cigar_roooms_guy by cigar_roooms_guy Feb 18, 2015 9:01 AM Flag

    Qihoo 360 Technology (QIHU) reported strong growth last quarter that came above the analysts’ consensus. This was driven by solid performance in its online advertising and internet game sales. Moreover, the management has projected a better than expected guidance for the fourth quarter. Interestingly, the company has not only surpassed the analyst’s expectations but even exceeded its own estimates on various metrics. Although the stock is currently at its 52-week low but we have some strong numbers to back on and a promising outlook ahead.

    Strong expectations for the future

    Qihoo’s high expectations can be justified by its strategic moves to strengthen its business. During the quarter, it completed the integration of Media V, which will bolster its tepid advertising performance. Media V has vast experience in digital advertising platform and data analysis along with a huge advertiser base. While talking to Global times, Qihoo’s Senior Vice President Yu Guangdong said “For Qihoo 360, cooperation with Media V could improve our advertising business and build more ad connections so as to upgrade our ability to generate more revenue through advertising.”

NXTM
18.84+0.52(+2.84%)May 27 4:00 PMEDT